MedPath

The efficacy of droxidopa fot the patients with MAPT mutation and PSP evaluated by tau imaging.

Not Applicable
Recruiting
Conditions
The patients with frontotemporal dementia harboring MAPT N279K and progressive supranuclear palsy-Richardson type.
Registration Number
JPRN-UMIN000030527
Lead Sponsor
Juntendo University School of Medicine
Brief Summary

We examined tau-imaging for 14 patients with sporadic PSP and one patient with MAPT N279K. The results partially showed the spreading and increased accumulation of tau protein. Our sequential examinations confirmed the increased tau protein in vivo.

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
15
Inclusion Criteria

Not provided

Exclusion Criteria

Exclude the patients not defined the above criteria.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
PBB3-PET, basic examinations of blood, urine, and cerebrospinal fluids. Metabolome, cognitive test, brain MRI, and SPECT.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath